TransMedics Group Inc (NASDAQ:TMDX) stock is trading lower on Tuesday.
The organ transplant medtech company reported a third-quarter EPS of $0.12, missing the consensus of $0.30. It reported sales of $108.8 million, up 64% year over year, but it missed the consensus of $115 million.
The increase was driven primarily by the increased utilization of the Organ Care System (OCS) across all three organs through the National OCS Program (NOP) and additional revenue generated by TransMedics logistics services.
Gross margin was 56%, compared to 61% in the third quarter of 2023, due to a higher proportion of service revenue than product revenue, which carries a higher margin in 2024.
Guidance: TransMedics expects fiscal year 2024 sales of $425 million—$445 million, compared to the consensus of $444.4 million.
“Overall, we remain well on track to reach our stated target of achieving 10,000 OCS transplant cases per year in the U.S. by 2028,” said Waleed Hassanein, President and CEO.
William Blair says the third-quarter results and 2024 outlook are still solid but believes investors will be disappointed in the performance given the company’s historical beat-and-raise cadence.
The analyst said TransMedics stands out as one of the top organic growth stories in their coverage. The company has a significant untapped market opportunity that it can leverage in the future.
The analyst noted that many investors had understandable concerns about the company’s third-quarter performance as the period approached.
The worries were driven by several factors, including management’s second-quarter remarks about traditionally weaker industry volumes during this time, several planes undergoing scheduled maintenance, and a recent slowdown in U.S. organ transplant volumes.
The analyst notes industry data indicating low- to mid-single-digit declines across various organs, including a 5% drop in heart and liver transplants and a 3% dip in lung transplants.
Analyst Reactions:
- Needham maintains TransMedics with a Buy and lowers the price target from $208 to $109.
- Baird reiterates the Outperform rating for TransMedics and lowers the price target from $200 to $150.
- Canaccord Genuity maintains TransMedics with a Buy, lowering the price target from $169 to $109.
- Oppenheimer keeps the Outperform rating and lowers the price target from $200 to $125.
- JP Morgan also maintains the Overweight rating, lowering the price target from $173 to $116.
- Piper Sandler maintains the Overweight rating and $180 price target.
Price Action: TMDX stock is trading 30.6% lower at $87.68 at last check Tuesday.
Read Next:
- Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
Comments